Please login to the form below

Not currently logged in
Email:
Password:

Iclusig

This page shows the latest Iclusig news and features for those working in and with pharma, biotech and healthcare.

Takeda's gamble on Ariad pays off with Alunbrig approval

Takeda's gamble on Ariad pays off with Alunbrig approval

Takeda agreed to buy Ariad earlier this year in a $5.2bn deal, which included already-marketed haematological cancer drug Iclusig (ponatinib) as well as a pipeline of oncology candidates headed ... Iclusig - approved for chronic myeloid leukaemia (CML)

Latest news

  • Takeda agrees $5.2bn deal to buy Ariad Takeda agrees $5.2bn deal to buy Ariad

    The deal - which has been approved by both companies' boards - will give Takeda rights to haematological cancer drug Iclusig (ponatinib) as well as a pipeline of oncology candidates currently headed by ... Analysts suggested Weber's first deal could be a

  • Ariad files early marketing application for brigatinib Ariad files early marketing application for brigatinib

    The filing of brigatinib is a big boost for Ariad, which needs new revenue streams to sit alongside its only marketed drug, Iclusig (ponatinib) for chronic myeloid leukaemia (CML). ... Earlier this month it sold its EU operations as well as Iclusig

  • Angelini to market Ariad’s Iclusig in Eastern Europe Angelini to market Ariad’s Iclusig in Eastern Europe

    Angelini to market Ariad’ s Iclusig in Eastern Europe. Comes after leukaemia drug passes EMA safety review. ... Angelini has the experience and geographic reach to market and distribute Iclusig in Central and Eastern Europe,” he added.

  • EMA safety panel rules no change needed for Ariad's Iclusig EMA safety panel rules no change needed for Ariad's Iclusig

    EMA safety panel rules no change needed for Ariad's Iclusig. Positive news comes after blood clot concerns. ... The European Medicines Agency (EMA) has ruled the continued use of Ariad's cancer therapy Iclusig unchanged in the EU.

  • Halozyme to resume pancreatic cancer study Halozyme to resume pancreatic cancer study

    Most recently Ariad's leukaemia drug Iclusig faced safety investigations in both the US and EU after some patients developed blood clots, forcing the company to revise the drug's safety

More from news
Approximately 13 fully matching, plus 6 partially matching documents found.

Latest Intelligence

  • Deal Watch January 2017 Deal Watch January 2017

    With an enterprise value of $5.2bn this acquisition brings access to Iclusig (ponatinib), approved for chronic myeloid leukaemia (CML) and acute lymphoblastic leukaemia (ALL), as well as brigatinib in phase ... Iclusig sales are forecast to reach between

  • Deal Watch May 2016 Deal Watch May 2016

    With a headline value of $140m out-licensing the European rights will enable Ariad to focus on Iclusig in the US. ... 182. Ariad Pharm/ Incyte. Acquisition and licence. Ariad's European operations; $140m upfront with tiered royalties on European sales of

  • Deal Watch table for December 2014 Deal Watch table for December 2014

    Iclusig (ponatinib), inhibitor of BCR-ABL, for resistant and intolerant CML and Ph ALL (JP NDA).

  • Interview: Harvey Berger and Timothy Clackson, Ariad Interview: Harvey Berger and Timothy Clackson, Ariad

    Brian collaborated with us through the development of Iclusig and that was a truly symbiotic relationship,” says Clackson. ... We hope that Iclusig will be the gift that keeps on giving both in CML and in other indications,” says Clackson.

More from intelligence
Approximately 1 fully matching, plus 3 partially matching documents found.

Latest appointments

  • Jennifer Herron appointed as chief commercial officer of ARIAD Jennifer Herron appointed as chief commercial officer of ARIAD

    for Iclusig and, if approved, brigatinib.”. ... I look forward to working with the team to maximize the commercial performance of Iclusig, prepare for the potential US launch of brigatinib, and collaborate with R&D colleagues to further

  • Ariad founder Harvey Berger to retire as CEO and chairman Ariad founder Harvey Berger to retire as CEO and chairman

    Under his leadership, Ariad brought Iclusig to the market for the treatment of patients with refractory chronic myeloid leukaemia and Philadelphia chromosome-positive acute lymphoblastic leukaemia, approved in the US, EU,

  • Hugh Cole leaves Shire for Ariad Hugh Cole leaves Shire for Ariad

    Hugh Cole leaves Shire for Ariad. Appointed chief business officer at company behind Iclusig. ... This includes its only current marketed product Iclusig, which is recommended to treat chronic myeloid leukaemia and T315I-positive Philadelphia chromosome

  • Ariad appoints new board member Ariad appoints new board member

    Ariad will look to benefit Denner's experience as it prepares to grow the market share of leukaemia drug Iclusig (ponatinib).

  • Jonathan Dickinson joins Ariad from BMS Jonathan Dickinson joins Ariad from BMS

    Jonathan Dickinson joins Ariad from BMS. Will lead launch of chronic myeloid leukaemia treatment Iclusig. ... He joins at an important time for Ariad in Europe as it prepares to launch its chronic myeloid leukaemia treatment Iclusig (ponatinib), pending

More from appointments
Approximately 0 fully matching, plus 5 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
GCI Health

GCI Health London is a young, vibrant powerhouse in the European industry with a mission to redefine healthcare communications, starting...

Latest intelligence

EU
Innovation in merger control and the impact on the pharmaceutical sector
Is focusing on pipeline products enough to assess regulatory risks?...
Nudge-nudge, think-think
Chris Ross examines the personal complexities of human behaviour – and explains why fun, emotion and peer endorsement could be key to designing effective behavioural change programmes...
Peoples Award
Quality in Care Diabetes 2018: the best in innovative diabetes care
Awards highlight new evidence-based approaches to improving care...

Infographics